title: [Activity of natural coagulation inhibitor proteins in the acute phase of ischaemic stroke].
abstract: BACKGROUND
  Decreased activity of natural anticoagulants (antithrombin-lll, protein C, protein S) rarely causes cerebral ischaemia, however it can be found frequently in acute phase of ischaemic stroke. The authors' aim was to investigate whether the decreased activity of natural anticoagulants is accompanied by worsening of symptoms in ischaemic stroke.
  
  
  METHODS
  Sixty-eight acute ischaemic stroke patients were investigated. Severity of symptoms were assessed and followed by the NIH Stroke Scale. Antithrombin-Ill, protein C, protein S activities, and concentration of C-reactive protein (CRP) were measured within 48 hours after onset of ischaemic stroke.
  
  
  RESULTS
  Progressing stroke was found in 29% of patients. Decreased activity of at least one natural anticoagulant proteins was present in 31% of patients. Progression of stroke symptoms occurred in 76% of patients with decreased natural anticoagulant activity, while this proportion was only 9% in those with normal natural coagulation inhibitor protein activity (p < 0.01). Progressing stroke was also more frequent in patients with elevated CRP value (60%) than in those with normal CRP level (11%; p < 0.05). Decreased activity of natural anticoagulants was more frequent in patients with elevated CRP concentration compared with patients with normal CRP.
  
  
  CONCLUSIONS
  The results demonstrate the importance of decreased activity of natural anticoagulants in acute phase of ischaemic stroke. This abnormality was present in about 1/3 of stroke patients. The decreased activity of natural coagulant inhibitor proteins may play an important role in development of progressing stroke thus indicating unfavourable outcome.
authors.affiliation: Debreceni Egyetem, Orvos- es Egészségtudományi Centrum, Neurológiai Klinika, Debrecen. olah@jaguar.dote.hu
authors.forename: László
authors.initials: L
authors.lastname: Oláh
authors.forename: Tünde
authors.initials: T
authors.lastname: Csépány
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Bereczky
authors.forename: Adrienne
authors.initials: A
authors.lastname: Kerényi
authors.forename: Mária
authors.initials: M
authors.lastname: Misz
authors.forename: János
authors.initials: J
authors.lastname: Kappelmayer
authors.forename: László
authors.initials: L
authors.lastname: Csiba
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000378:metabolism*; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors*; D002545:Brain Ischemia / Q000150:complications*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011486:Protein C / Q000378:metabolism*; D017293:Protein S / Q000378:metabolism*; D012720:Severity of Illness Index; D020521:Stroke / Q000097:blood* / Q000209:etiology / Q000378:metabolism
chemical_list: D001779:Blood Coagulation Factors; D011486:Protein C; D017293:Protein S; D000990:Antithrombin III